胸肌前假体乳房再造联合乳房切除术后放疗
回顾性分析54例女性93侧胸肌前假体乳房再造(39例双侧、15例单侧),单侧接受乳房切除术后放疗。中位随访自乳房切除及组织扩张器置入19个月、自假体置入9个月。放疗侧与非放疗侧并发症率分别为手术部位感染18.5%对7.7%、血清肿5.6%对5.1%、皮瓣坏死1.9%对2.6%、伤口裂开1.9%对7.7%、包膜挛缩1.9%对0%、血肿1.9%对2.6%、外露1.9%对0%。单因素分析未发现与任何并发症相关的危险因素。目前96%患者完成再造,81侧假体再造成功(放疗侧45侧、非放疗侧36侧)。
要点
- 早期数据显示胸肌前假体乳房再造联合乳房切除术后放疗结果良好。
- 乳房切除术后放疗不应视为胸肌前假体乳房再造的绝对禁忌证。
- 单因素分析未发现与任何并发症相关的危险因素,包括放疗。
核心结论
- 胸肌前假体乳房再造联合乳房切除术后放疗的早期数据结果良好,乳房切除术后放疗不应视为胸肌前假体乳房再造的绝对禁忌证。
研究设计与样本
- 回顾性连续病例分析,纳入54例女性共93侧胸肌前假体乳房再造(39例双侧、15例单侧),均为即刻两阶段再造并接受单侧乳房切除术后放疗。
主要发现
- 中位随访自乳房切除及组织扩张器置入为19个月,自假体置入为9个月。
- 放疗侧与非放疗侧并发症率:手术部位感染18.5%对7.7%;血清肿5.6%对5.1%;乳房皮肤皮瓣坏死1.9%对2.6%;伤口裂开1.9%对7.7%;包膜挛缩1.9%对0%;血肿1.9%对2.6%;外露1.9%对0%。
- 单因素分析未发现与任何并发症相关的危险因素,包括放疗、手术部位感染、非计划再入院和非计划重返手术室。
- 目前96%患者完成再造,81侧假体再造成功(放疗侧45侧、非放疗侧36侧)。
临床怎么用
- 作者结论认为早期数据结果良好,乳房切除术后放疗不应视为胸肌前假体乳房再造的绝对禁忌证。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Two-stage subpectoral implant-based breast reconstruction is the most common method for breast reconstruction. Recent advances in surgical techniques and technology have made prepectoral implant-based breast reconstruction feasible. There are limited data on outcomes after prepectoral implant-based breast reconstruction and postmastectomy radiation therapy. METHODS: A retrospective review of consecutive patients undergoing immediate two-stage prepectoral implant-based breast reconstruction with postmastectomy radiation therapy was performed. Outcomes of irradiated breasts were compared with nonirradiated breasts in bilateral cases. RESULTS: Ninety-three cases of prepectoral implant-based breast reconstruction in 54 women who underwent immediate two-stage reconstruction (39 bilateral and 15 unilateral) and unilateral postmastectomy radiation therapy were identified. Mean follow-up was 19 months from mastectomy and tissue expander reconstruction and 9 months from implant placement. Crude complication rates in irradiated versus nonirradiated sides were as follows: surgical-site infection, 18.5 percent versus 7.7 percent; seroma, 5.6 percent versus 5.1 percent; mastectomy skin flap necrosis, 1.9 percent versus 2.6 percent; wound dehiscence, 1.9 percent versus 7.7 percent; capsular contracture, 1.9 percent versus 0 percent; hematoma, 1.9 percent versus 2.6 percent; and extrusion, 1.9 percent versus 0 percent. On univariate analysis, there were no risk factors associated with any complication, including radiation therapy, surgical-site infection, unplanned readmissions, and unplanned return to the operating room. To date, reconstruction has been completed in 96 percent of patients, with successful implant-based breast reconstruction in 81 breasts (45 irradiated breasts and 36 nonirradiated breasts). CONCLUSIONS: Early data of prepectoral implant-based breast reconstruction in patients with postmastectomy radiation therapy show promising results. Postmastectomy radiation therapy should not be an absolute contraindication to prepectoral implant-based breast reconstruction. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.
引用
- Elswick SM, Harless CA, Bishop SN, et al. Prepectoral Implant-Based Breast Reconstruction with Postmastectomy Radiation Therapy. Plast Reconstr Surg. 2018. PMID: 29878988. doi:10.1097/PRS.0000000000004453
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。